USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002)
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024) Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024. Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024 Learn More
USP Global Public Policy Position: Identifying and addressing vulnerabilities in the upstream medicines supply chain to build resilience and reduce drug shortages
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical… Learn More
USP Comment Letter to CMS: Response to Proposed Rule on Drug Classification in Electronic Health Benefits (2024)
USP Comment Letter submitted to Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment… Learn More

Document Classification

Topics